On July 22, Genscript Biotech rose 5.12% in regular trading, reaching HKD 15.44 per share with turnover of HKD 227 million.

On the news front, the company recently showcased its fully automated dark laboratory and AI bio-manufacturing capabilities at the World Artificial Intelligence Conference (WAIC), highlighting its deep collaboration with ByteDance in AI-driven drug discovery. ByteDance's protein structure model Protenix achieved a wet-experiment validation hit rate of up to 82% across seven drug targets, with the underlying experimental workflow supported by Genscript's TurboCHO high-throughput platform handling protein expression, purification, and efficacy screening.

Additionally, CARVYKTI posted Q2 net trade sales of approximately USD 657 million, up roughly 10% from Q1's USD 597 million. Profit-taking pressure triggered by the sequential growth deceleration was largely absorbed last week, with the stock recovering from its July 17 low of HKD 13.12. Today's advance represents a continuation of that technical rebound.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)